Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment

被引:249
作者
Konradi, C
Heckers, S
机构
[1] McLean Hosp, Charles D Baker Lab Neuroplast, Mailman Res Ctr, Belmont, MA 02478 USA
[2] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA 02129 USA
[3] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA
关键词
schizophrenia; glutamate; neuroplasticity; neurotoxicity; antipsychotic drugs; neuropathology;
D O I
10.1016/S0163-7258(02)00328-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The glutamate system is involved in many aspects of neuronal synaptic strength and function during development and throughout life. Synapse formation in early brain development, synapse maintenance, and synaptic plasticity are all influenced by the glutamate system. The number of neurons and the number of their connections are determined by the activity of the glutamate system and its receptors. Malfunctions of the glutamate system affect neuroplasticity and can cause neuronal toxicity. In schizophrenia, many glutamate-regulated processes seem to be perturbed. Abnormal neuronal development, abnormal synaptic plasticity, and neurodegeneration have been proposed to be causal or contributing factors in schizophrenia. Interestingly, it seems that the glutamate system is dysregulated and that N-methyl-D-aspartate receptors operate at reduced activity. Here we discuss how the molecular aspects of glutamate malfunction can explain some of the neuropathology observed in schizophrenia, and how the available treatment intervenes through the glutamate system. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:153 / 179
页数:27
相关论文
共 373 条
[1]   Serotonin model of schizophrenia: emerging role of glutamate mechanisms [J].
Aghajanian, GK ;
Marek, GJ .
BRAIN RESEARCH REVIEWS, 2000, 31 (2-3) :302-312
[2]   Assembly of presynaptic active zones from cytoplasmic transport packets [J].
Ahmari, SE ;
Buchanan, J ;
Smith, SJ .
NATURE NEUROSCIENCE, 2000, 3 (05) :445-451
[3]  
Akbarian S, 1996, J NEUROSCI, V16, P19
[4]  
Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO
[5]  
2-0
[6]   Emerging roles for novel antipsychotic medications in the treatment of schizophrenia [J].
Andersson, C ;
Chakos, M ;
Mailman, R ;
Lieberman, J .
PSYCHIATRIC CLINICS OF NORTH AMERICA, 1998, 21 (01) :151-+
[7]   Schizophrenia: the fundamental questions [J].
Andreasen, NC .
BRAIN RESEARCH REVIEWS, 2000, 31 (2-3) :106-112
[8]   Pieces of the schizophrenia puzzle fall into place [J].
Andreasen, NC .
NEURON, 1996, 16 (04) :697-700
[9]   Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats - Implications for tardive dyskinesia? [J].
Andreassen, OA ;
Jorgensen, HA .
PROGRESS IN NEUROBIOLOGY, 2000, 61 (05) :525-541
[10]   GLUTAMATE-INDUCED NEURONAL DEATH - A SUCCESSION OF NECROSIS OR APOPTOSIS DEPENDING ON MITOCHONDRIAL-FUNCTION [J].
ANKARCRONA, M ;
DYPBUKT, JM ;
BONFOCO, E ;
ZHIVOTOVSKY, B ;
ORRENIUS, S ;
LIPTON, SA ;
NICOTERA, P .
NEURON, 1995, 15 (04) :961-973